Thérèse Aurran

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals

Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance

Diffuse large B-cell lymphoma

Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding

Alemtuzumab for patients with chronic lymphocytic leukaemia

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

Multiple Myeloma

Overview of monoclonal B‐cell lymphocytosis

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang” (GOELAMS) : CLL2007FMP (for fit medically patients).

Autologous Stem Cell Transplantation (auto-SCT) in Elderly Patients with Multiple Myeloma (MM): Age per se Does Not Affect Outcome.